SCA
HIV

Stonebridge Capital Advisors’s CALYPTE BIOMEDICAL CORP NEW HIV Stock Holding History

Stonebridge Capital Advisors’s Portfolio HIV Stock Details HIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-11,800
Closed – – 160
2015
Q2 		$0 Hold
11,800
– – ﹤0.01% 155
2015
Q1 		$0 Hold
11,800
– – ﹤0.01% 156
2014
Q4 		$0 Hold
11,800
– – ﹤0.01% 155
2014
Q3 		$0 Hold
11,800
– – ﹤0.01% 158
2014
Q2 		$0 Hold
11,800
– – ﹤0.01% 153
2014
Q1 		$0 Hold
11,800
– – ﹤0.01% 147
2013
Q4 		$0 Buy
+11,800
New – ﹤0.01% 137

Stonebridge Capital Advisors's HIV Position: Q3 2015 in Review

Stonebridge Capital Advisors sold out of CALYPTE BIOMEDICAL CORP NEW (HIV) in Q3 2015, closing a stake of 11,800 shares.

Stonebridge Capital Advisors first reported a position in HIV in Q4 2013 and held it in 7 quarters. The position peaked at $0 in Q2 2015. 0 funds tracked by Wall St. Rank hold HIV as of Q3 2015.

  • Stonebridge Capital Advisors reported no remaining CALYPTE BIOMEDICAL CORP NEW position as of Q3 2015 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 11,800 CALYPTE BIOMEDICAL CORP NEW shares in Q3 2015.
  • Stonebridge Capital Advisors first reported a position in CALYPTE BIOMEDICAL CORP NEW in Q4 2013 and held it in 7 quarters.
  • Stonebridge Capital Advisors's CALYPTE BIOMEDICAL CORP NEW position peaked at $0 in Q2 2015.
  • 0 funds tracked by Wall St. Rank held CALYPTE BIOMEDICAL CORP NEW as of Q3 2015.

Based on Stonebridge Capital Advisors's 13F filing for Q3 2015, filed 23 Nov 2015.